Advertisement

HCC. Radioembolization Combined with Other Therapeutic Local and Systemic Treatment

  • Thomas Helmberger
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

Only in early stages of HCC resection, local ablative therapy, and transplantation are offering a chance of cure, whereas only a minority of patient will amenable for such a therapy. The majority of patients are presenting an intermediate or even advanced tumor stages where the therapeutic options are limited to transarterial and systemic molecular therapies. Radio embolization may augment the therapeutic armamentarium particularly in patients just not meeting the criteria for resection, percutaneous ablation or transplantation by downsizing/downgrading or in progressed disease where transarterial chemotherapy is contraindicated. Recent results of radio embolization in these settings and future directions will be discussed.

Keywords

National Comprehensive Cancer Network Milan Criterion Local Ablative Therapy Sharp Trial Multimodality Treatment Concept 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

AASLD

American Association for the Study of Liver Diseases

BCLC

Barcelona-Clinic Liver Cancer

BSC

Best supportive care

C-B

Child-Pugh

CR

Complete response

EASL

European Association for the Study of the Liver

ECOG

Eastern Cooperative Oncology Group

ENRY

European Network on Radioembolization with Yttrium-90 Resin Microspheres

EORTC

European Organization for Research and Treatment of Cancer

ESMO

European Society for Medical Oncology

Gd-EOB-DTPA

Gadoxetic acid (Promovist®, Bayer, Germany)

LTx

Liver transplantation

NCCN

National Comprehensive Cancer Network

NCI

National Cancer Institute

PR

Partial response

PVT

Portal-vein thrombosis

RE

Radio-embolization

Rx

Resection

SD

Stable disease

SHARP

Sorafenib HCC Assessment Randomized Protocol

TACE

Transarterial chemo-embolization

TAE

Transarterial embolization

TTP

Time to progression

UNOS

United Network for Organ Sharing

VT

Venous thrombosis

References

  1. Ahmadzadehfar H, Meyer C, Ezziddin S, Sabet A, Hoff-Meyer A, Muckle M, Logvinski T, Schild HH, Biersack HJ, Wilhelm K (2013) Hepatic volume changes induced by radioembolization with (90)Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 40(1):80–90PubMedCrossRefGoogle Scholar
  2. Anaya DA, Blazer DG, Abdalla EK (2008) Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma. Semin Interv Radiol 25(2):110–122CrossRefGoogle Scholar
  3. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedCentralPubMedCrossRefGoogle Scholar
  4. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57(4):821–829PubMedCrossRefGoogle Scholar
  5. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 56(6):1330–1335PubMedCrossRefGoogle Scholar
  6. Carr BI, Kondragunta V, Buch SC, Branch RA (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116(5):1305–1314PubMedCentralPubMedCrossRefGoogle Scholar
  7. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy MD, Brown DB (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248(4):617–625PubMedGoogle Scholar
  8. Chaudhury PK, Hassanain M, Bouteaud JM, Alcindor T, Nudo CG, Valenti D, Cabrera T, Kavan P, Feteih I, Metrakos P (2010) Complete response of hepatocellular carcinoma with sorafenib and Y radioembolization. Curr Oncol 17(5):67–69PubMedCentralPubMedGoogle Scholar
  9. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258(2):627–634PubMedCrossRefGoogle Scholar
  10. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A (2012) Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13(1):e11–e22PubMedCentralPubMedCrossRefGoogle Scholar
  11. Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, Hendler AL, Goin JE (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41(10):1673–1681PubMedGoogle Scholar
  12. D’Avola D, Lnarrairaegui M, Bilbao JI, Martinez-Cuesta A, Alegre F, Herrero JI, Quiroga J, Prieto J, Sangro B (2009) A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology 56(96):1683–1688PubMedGoogle Scholar
  13. Denys A, Prior J, Bize P, Duran R, De Baere T, Halkic N, Demartines N (2012) Portal vein embolization: what do we know? Cardiovasc Interv Radiol 35(5):999–1008CrossRefGoogle Scholar
  14. Di Sandro S, Giacomoni A, Slim A, Lauterio A, Mangoni I, Mihaylov P, Pirotta V, Aseni P, De Carlis L (2012) Living donor liver transplantation for hepatocellular carcinoma: the impact of neo-adjuvant treatments on the long term results. Hepatogastroenterology 59(114):505–510PubMedGoogle Scholar
  15. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) J Hepatol 56(4): 908–943Google Scholar
  16. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255PubMedCrossRefGoogle Scholar
  17. Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R (2009) Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 16(6):1587–1596PubMedCrossRefGoogle Scholar
  18. Garden OJ (2011) Pushing the limits of surgical management in patients with hepatocellular carcinoma. Br J Surg 98(9):1183–1184PubMedCrossRefGoogle Scholar
  19. Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA (2011) Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg 98(9):1201–1208PubMedCrossRefGoogle Scholar
  20. Gulec SA, Pennington K, Hall M, Fong Y (2009) Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol 7:6. doi: 10.1186/1477-7819-7-6
  21. Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G (2010) Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52(5):1741–1749PubMedCrossRefGoogle Scholar
  22. Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, Salem R, Lewandowski RJ (2012) Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Interv Radiol 35(5):1094–1101CrossRefGoogle Scholar
  23. Inarrairaegui M, Thurston KG, Bilbao JI, D’Avola D, Rodriguez M, Arbizu J, Martinez-Cuesta A, Sangro B (2010) Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 21(8):1205–1212PubMedCrossRefGoogle Scholar
  24. Inarrairaegui M, Pardo F, Bilbao JI, Rotellar F, Benito A, D’Avola D, Herrero JI, Rodriguez M, Marti P, Zozaya G, Dominguez I, Quiroga J, Sangro B (2012) Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 38(7):594–601PubMedCrossRefGoogle Scholar
  25. Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, Miller F, Ryu RK, Ibrahim S, Sato KT, Kulik LM, Mulcahy MF, Omary R, Murthy R, Reiser MF, Salem R (2008) Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 53(9):2556–2563PubMedCrossRefGoogle Scholar
  26. Jelic S and Sotiropoulos GC (2010) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v59-v64Google Scholar
  27. Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21(2):224–230PubMedCrossRefGoogle Scholar
  28. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Haines KG 3rd, Salem R (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572–586PubMedCrossRefGoogle Scholar
  29. Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, Li AK (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40(3):583–592PubMedCrossRefGoogle Scholar
  30. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9(8):1920–1928PubMedCrossRefGoogle Scholar
  31. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390PubMedCrossRefGoogle Scholar
  32. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M (2011) Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 18(2):413–420PubMedCrossRefGoogle Scholar
  33. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchiano A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, and Spreafico C (2012) Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: A phase II study. Hepatology, Accepted Article. doi: 10.1002/hep.26014
  34. Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, Riaz A, Gupta R, Vouche M, Gates VL, Miller FH, Omary RA, Salem R (2012) Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. J Hepatol. doi: 10.1016/j.jhep.2012.09.003
  35. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A, Pitton M (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12(8):1260–1267PubMedCrossRefGoogle Scholar
  36. Raoul JL, Boucher E, Rolland Y, Garin E (2010) Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 7(1):41–49PubMedCrossRefGoogle Scholar
  37. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, Miller FH, Sato KT, Omary RA, Salem R (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185–1193PubMedCrossRefGoogle Scholar
  38. Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 9(6):739–745PubMedCrossRefGoogle Scholar
  39. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1):52–64PubMedCrossRefGoogle Scholar
  40. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, 3rd, and Mulcahy MF (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(2): 497–507 e2Google Scholar
  41. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, Quiroga J, Prieto J (2006) Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66(3):792–800PubMedCrossRefGoogle Scholar
  42. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Inarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S (2011) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54(3):868–878PubMedCrossRefGoogle Scholar
  43. Seidensticker R, Seidensticker M, Damm R, Mohnike K, Schutte K, Malfertheiner P, Van Buskirk M, Pech M, Amthauer H, Ricke J (2012) Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Interv Radiol 35(5):1109–1118CrossRefGoogle Scholar
  44. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, Iaccarino G, Benassi M, Ettorre GM, Maini CL (2010) Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 51(9):1377–1385PubMedCrossRefGoogle Scholar
  45. Theysohn JM, Schlaak JF, Muller S, Ertle J, Schlosser TW, Bockisch A, Lauenstein TC (2012) Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. J Vasc Interv Radiol 23(7):949–952PubMedCrossRefGoogle Scholar
  46. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O’Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A (2010) Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28(25):3994–4005PubMedCentralPubMedCrossRefGoogle Scholar
  47. Toso C, Mentha G, Kneteman NM, Majno P (2010) The place of downstaging for hepatocellular carcinoma. J Hepatol 52(6):930–936PubMedCrossRefGoogle Scholar
  48. Vogl TJ, Nour-Eldin NE, Emad-Eldin S, Naguib NN, Trojan J, Ackermann H, Abdelaziz O (2011) Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol 17(10):1267–1275PubMedCentralPubMedCrossRefGoogle Scholar
  49. Woodall CE, Scoggins CR, Ellis SF, Tatum CM, Hahl MJ, Ravindra KV, McMasters KM, Martin RC 2nd (2009) Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg 208(3):375–382PubMedCrossRefGoogle Scholar
  50. Worns MA, Weinmann A, Schuchmann M, Galle PR (2009) Systemic therapies in hepatocellular carcinoma. Dig Dis 27(2):175–188PubMedCrossRefGoogle Scholar
  51. Wu ZJ, Cai J, Xu AB, Su XQ, Wang XQ, Zhang YX, Shao BF, Li YJ, Chu KY (2011) Combined three-dimensional conformal radiotherapy plus transcatheter arterial chemoembolization and surgical intervention for portal vein tumor thrombus in patients with hepatocelular carcinoma. Zhonghua Yi Xue Za Zhi 91(40):2841–2844PubMedGoogle Scholar
  52. Yoo H, Kim JH, Ko GY, Kim KW, Gwon DI, Lee SG, Hwang S (2011) Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. Ann Surg Oncol 18(5):1251–1257PubMedCrossRefGoogle Scholar
  53. Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Park JH, Suh DJ (2012) Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 82(5):2004–2011PubMedCrossRefGoogle Scholar
  54. Yoshidome H, Takeuchi D, Kimura F, Shimizu H, Ohtsuka M, Kato A, Furukawa K, Yoshitomi H, Miyazaki M (2011) Treatment strategy for hepatocellular carcinoma with major portal vein or inferior vena cava invasion: a single institution experience. J Am Coll Surg 212(5):796–803PubMedCrossRefGoogle Scholar
  55. Zhang XB, Wang JH, Yan ZP, Qian S, Du SS, Zeng ZC (2009) Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer 115(6):1245–1252PubMedCrossRefGoogle Scholar
  56. Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H (2010) Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 21(3):326–332PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Institute of Diagnostic and Interventional Radiology, Neuroradiology and Nuclear MedicineKlinikum BogenhausenMunichGermany

Personalised recommendations